Claims for Patent: 9,121,028

Summary for Patent: 9,121,028

Title:	Selective gene expression in plants
Abstract:	This invention discloses methods for providing plants with selective expression of a target RNA and methods for evaluating an expression pattern of a target RNA in a plant. Also disclosed are transgenic plants having recombinant DNA for expressing a protein using a promoter functional in multiple tissues, and recombinant DNA for suppressing expression of the protein using a promoter functional in fewer than the multiple tissues.
Inventor(s):	Chomet; Paul S. (Mystic, CT), Edgerton; Michael D. (St. Louis, MO)
Assignee:	Monsanto Technology LLC (St. Louis, MO)
Application Number:	11/518,571
Patent Claims:	1. A method of providing plants with selective expression of an exogenous RNA, comprising: a) providing a set of first parent plants each expressing a recombinant DNA construct comprising a promoter operably linked to (i) DNA encoding an exogenous RNA, wherein said exogenous RNA is different for each of said first parent plants, and (ii) DNA encoding either a 5' UTR or a 3' UTR which is transcribed to a target RNA, wherein said target RNA is common to the set of first parent plants, and wherein said exogenous RNA and said target RNA are on the same RNA transcript; b) providing multiple second parent plants each expressing a recombinant DNA construct comprising a second promoter operably linked to DNA for suppressing expression of the target RNA, wherein each said second promoter is non-constitutive and is different for each of said multiple second parent plants; c) hybridizing said first parent plants and each of said multiple second parent plants to generate a heterogeneous population of hybrid progeny with regard to expression of said exogenous RNA; and d) producing a hybrid progeny with selective expression of said exogenous RNA relative to expression in said first parent plants. 2. The method of claim 1, wherein said DNA for suppressing is transcribed to double-stranded RNA. 3. The method of claim 1, wherein said exogenous RNA comprises: (a) coding RNA, or (b) non-coding RNA, or (c) both coding and non-coding RNA. 4. The method of claim 1, wherein said exogenous RNA comprises non-coding RNA selected from at least one of the group consisting of a promoter, a promoter enhancer element, a 3' untranslated region, a 5' untranslated region, a polyadenylation sequence, and an intron. 5. The method of claim 1, wherein said hybrid progeny comprises hybrid seed. 6. The method of claim 1, wherein said hybrid progeny comprises hybrid progeny plants. 7. The method of claim 1, wherein said second promoter is a spatially specific promoter, a temporally specific promoter, a developmentally specific promoter, or an inducible promoter. 8. A method of evaluating a constitutive, non-constitutive, spatial, temporal, developmental, or inducible expression pattern of an exogenous RNA in a plant, comprising: a) performing crosses of a set of first parent plants with multiple second parent plants, wherein each of said first parent plants expresses in its cells a recombinant DNA construct comprising a promoter operably linked to (i) DNA encoding an exogenous RNA, wherein said exogenous RNA is different for each of said first parent plants, and (ii) DNA encoding either a 5' UTR or a 3' UTR which is transcribed to a target RNA, wherein said target RNA is common to the set of first parent plants, and wherein said exogenous RNA and said target RNA are on the same RNA transcript, and each of said multiple second parent plants has in its genome a silencing sequence comprising a second promoter operably linked to DNA for suppressing expression of said target RNA, wherein each said second promoter is non-constitutive and is different for each of said multiple second parent plants, and said crosses result in the formation of a heterogeneous population of hybrid progeny; and b) evaluating said hybrid progeny for constitutive, non-constitutive, spatial, temporal, developmental, or inducible expression patterns of said exogenous RNA. 9. The method of claim 8, wherein said silencing is double-stranded RNA-mediated silencing. 10. The method of claim 8, wherein said exogenous RNA comprises: (a) coding RNA, or (b) non-coding RNA, or (c) both coding and non-coding RNA. 11. The method of claim 8, wherein said exogenous RNA comprises non-coding RNA selected from at least one of the group consisting of a promoter, a promoter enhancer element, a 3' untranslated region, a 5' untranslated region, a polyadenylation sequence, and an intron. 12. The method of claim 8, wherein said hybrid progeny comprises hybrid seed. 13. The method of claim 8, wherein said hybrid progeny comprises hybrid progeny plants. 14. The method of claim 8, wherein said second promoter is a spatially specific promoter, a temporally specific promoter, a developmentally specific, or an inducible promoter.

Details for Patent 9,121,028

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26